DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

NEWS RELEASE

Released: March 27, 2019

Defense Health Program
Department of Defense Kidney Cancer Research Program
Funding Opportunities for Fiscal Year 2019 (FY19)

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support research of exceptional scientific merit in the area of kidney cancer. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY19 KCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in May 2019. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the government.


Award Mechanism Eligibility Key Mechanism Elements Funding
Concept Award Investigators at all academic levels.
  • Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.
  • Emphasis on innovation.
  • Funding for clinical trials not allowed.
  • Preliminary data not allowed.
  • Blinded review.
  • Maximum funding of $75,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 1 year.
Idea Development Award Established Investigators:
Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or

Early Career Investigators:
Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.
  • Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.
  • Preliminary data required.
  • Innovation and Impact the most important review criteria.
  • Funding for clinical trials not allowed.
  • FY19 KCRP Areas of Emphasis strongly encouraged.
  • Maximum funding of $400,000 in direct costs (plus indirect costs).
  • Maximum period of performance is 2 years.
Translational Research Partnership Award Investigators at or above the level of Assistant Professor (or equivalent).
  • Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.
  • Supports translational correlative studies.
  • Preliminary data required.
  • Funding for clinical trials not allowed.
  • Maximum funding of $600,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.
Kidney Cancer Academy Dean Award Dean must be an independent, established kidney cancer researcher with a record of kidney cancer research funding and publications in peer-reviewed journals.
  • Supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership.
  • Academy Dean will oversee an interactive virtual academy of ECIs and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the ECIs.
  • Maximum funding of $500,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 4 years.
Kidney Cancer Academy Early Career Investigator Award Within 3 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline.

Letter attesting to eligibility required.
  • Supports addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.
  • ECIs whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
  • Requires Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding.
  • Designated Mentor not required to be at the same institution as the ECI.
  • Preliminary data required.
  • Clinical trials allowed.
  • Maximum funding of $725,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 4 years.
Clinical Consortia Award Independent Investigators at or above the level of Assistant Professor (or equivalent).
  • Supports development of a consortium that will facilitate rapid execution of collaborative Phase II or Phase I/II clinical trials to bring to market high-impact, novel therapeutic interventions that will ultimately and significantly decrease impact of kidney cancer.
  • Funds may not be used for research or development of clinical protocols.
  • Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged.
  • One (1) Coordinating Center and three (3) Clinical Trial Sites will be selected and be jointly responsible for proposing, selecting, and conducting trials.
  • Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer.
  • Consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends.
Coordinating Center:
  • Maximum funding of $3,000,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.

Clinical Trial Sites:
  • Maximum funding of $600,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Wednesday, March 27, 2019